Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 13/20 | 0.64 |
| ▸ | CES1 | P23141 | 12/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204051 | 0.95 | CES2 (0.64) | CES2CES1ALOX15HTTPARP1 | |
| SCHEMBL31554264 | 0.85 | CES2 (0.52) | CES2CES1PARP1POLBTSHR | |
| SCHEMBL31554270 | 0.85 | CES2 (0.52) | CES2CES1PARP1POLBTSHR | |
| SCHEMBL4229652 | 0.84 | CES2 (0.61) | CES2CES1PARP1KMT2ARAB9A | |
| SCHEMBL6142583 | 0.84 | CES2 (0.45) | CES2CES1ALOX15HTTKMT2A | |
| SCHEMBL16503702 | 0.83 | CES2 (0.82) | CES2CES1PARP1RAB9APOLB | |
| SCHEMBL39515 | 0.82 | ALDH1A1 (0.64) | ALOX15HTTPARP1KMT2ARAB9A | |
| SCHEMBL649996 | 0.81 | CES2 (0.80) | CES2CES1KMT2ARAB9AMAPT | |
| Benzil SCHEMBL29124640 | 0.80 | CES2 (0.88) | CES2CES1ALOX15PARP1KMT2A | |
| Benzil SCHEMBL9517636 | 0.80 | CES2 (1.00) | CES2CES1ALOX15PARP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493183-B1 | PROCESS FOR MAKING AIR GAP CONTAINING SEMICONDUCTING DEVICES AND RESULTING SEMICONDUCTING DEVICE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7381850-B2 | Multifunctional unsymmetrically substituted monomers and polyarylene compositions therefrom | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060267000-A1 | Multifunctional unsymmetrically substituted monomers and polyarylene compositions therefrom | DOW GLOBAL TECHNOLOGIES INC. | 2006-11-30 | — | — | US | disclosed |
| US-6946382-B2 | Process for making air gap containing semiconducting devices and resulting semiconducting device | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050124172-A1 | Process for making air gap containing semiconducting devices and resulting semiconducting device | DOW GLOBAL TECHNOLOGIES LLC | 2005-06-09 | — | — | US | disclosed |
| EP-1493183-A2 | PROCESS FOR MAKING AIR GAP CONTAINING SEMICONDUCTING DEVICES AND RESULTING SEMICONDUCTING DEVICE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004089862-A2 | MULTIFUNCTIONAL UNSYMMETRICALLY SUBSTITUTED MONOMERS AND POLYARYLENE COMPOSITIONS THEREFROM | DOW GLOBAL TECHNOLOGIES INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2003085719-A2 | PROCESS FOR MAKING AIR GAP CONTAINING SEMICONDUCTING DEVICES AND RESULTING SEMICONDUCTING DEVICE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2001089527-A2 | PHARMACEUTICAL COMPOSITION COMPRISING LORATADINE AND A NASAL DECONGESTANT | SCHERING CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060267000-A1 | Multifunctional unsymmetrically substituted monomers and polyarylene compositions therefrom | WASF2, DDT, CAD | CES2 1963/4885CES1 4150/4885ALOX15 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.